Profile data is unavailable for this security.
About the company
JIANSU HENGRUI MEDICINE CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.
- Revenue in CNY (TTM)25.76bn
- Net income in CNY5.85bn
- Incorporated1997
- Employees24.43k
- LocationJiangsu Hengrui Medicine Co LtdNo.7 Kunlunshan RoadLianyungang Eco & Tech Development ZoneLIANYUNGANG 222000ChinaCHN
- Phone+86 51 881220983
- Fax+86 51 885453845
- Websitehttp://www.hrs.com.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WuXi AppTec Co Ltd | 15.41bn | 2.46bn | 249.81bn | 21.74k | 97.58 | 7.46 | -- | 16.21 | 1.06 | 1.06 | 6.58 | 13.80 | 0.4287 | 5.32 | 4.16 | 708,632.10 | 6.90 | -- | 8.46 | -- | 37.36 | -- | 16.10 | -- | 2.94 | 427.09 | 0.128 | -- | 33.89 | -- | -17.96 | -- | -- | -- |
| WuXi Biologics (Cayman) Inc | 4.32bn | 1.30bn | 260.14bn | 5.69k | 200.15 | 18.36 | 159.71 | 60.19 | 0.3752 | 0.3752 | 1.25 | 4.09 | 0.2794 | 5.43 | 3.27 | 898,927.60 | 8.35 | 7.79 | 9.84 | 9.92 | 41.55 | 40.35 | 29.89 | 21.47 | 2.77 | -- | 0.2108 | 0.00 | 57.18 | 64.39 | 60.77 | 89.05 | 129.29 | -- |
| Jiangsu Hengrui Medicine Co Ltd | 25.76bn | 5.85bn | 458.53bn | 24.43k | 68.14 | 13.47 | -- | 17.80 | 1.26 | 1.26 | 5.54 | 6.39 | 0.8808 | 2.18 | 4.55 | 1,054,261.00 | 19.96 | 20.74 | 22.56 | 23.67 | 86.89 | 86.78 | 22.66 | 23.40 | 6.08 | -- | 0.00 | 15.59 | 33.70 | 25.59 | 31.05 | 28.59 | 13.46 | 46.37 |
| DAIICHI SANKYO COMPANY, LIMITED | 62.06bn | 7.35bn | 506.95bn | 15.35k | 63.19 | 5.51 | 46.97 | 8.17 | 59.71 | 59.71 | 504.59 | 685.34 | 0.4765 | 1.86 | 3.30 | 64,007,560.00 | 5.64 | 4.14 | 6.65 | 5.05 | 65.93 | 64.23 | 11.83 | 8.47 | 3.86 | -- | 0.1212 | 55.53 | 5.60 | 1.32 | 37.90 | 22.53 | -11.09 | 3.13 |
| CSL Limited | 60.38bn | 13.87bn | 678.68bn | 27.00k | 48.95 | 15.73 | 40.78 | 11.24 | 6.27 | 6.27 | 27.28 | 19.52 | 0.6588 | 1.20 | 5.19 | 460,298.80 | 15.14 | 16.43 | 17.93 | 19.80 | 57.11 | 54.46 | 22.98 | 21.56 | 1.37 | 20.21 | 0.4787 | 44.45 | 7.17 | 10.21 | 9.58 | 8.80 | 27.01 | 9.79 |
Data as of Nov 30 2020. Currency figures normalised to Jiangsu Hengrui Medicine Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
7.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 31 Oct 2020 | 69.14m | 1.31% |
| GF Fund Management Co., Ltd.as of 30 Jun 2020 | 56.33m | 1.06% |
| China Investment Corp. (Investment Management)as of 30 Sep 2020 | 49.27m | 0.93% |
| E Fund Management Co., Ltd.as of 30 Jun 2020 | 46.00m | 0.87% |
| China Asset Management Co., Ltd.as of 06 Nov 2020 | 41.04m | 0.78% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2020 | 30.23m | 0.57% |
| UBS Asset Management (Singapore) Ltd.as of 30 Sep 2020 | 28.42m | 0.54% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2020 | 24.17m | 0.46% |
| UBS Asset Management (Hong Kong) Ltd.as of 30 Sep 2020 | 21.66m | 0.41% |
| JPMorgan Asset Management (Asia Pacific) Ltd.as of 31 Oct 2020 | 21.09m | 0.40% |
More ▼
Data from 30 Jun 2020 - 26 Nov 2020Source: FactSet Research Systems Inc.
